

activation, normal T expressed and secreted protein (RANTES) [RANTES], monocyte chemotactic protein-2 (MCP-2) [MCP-2], monocyte chemotactic protein-3 (MCP-3) [MCP-3], monocyte chemotactic protein-4 (MCP-4) [MCP-4], eotaxin, macrophage inflammatory protein-1 α (MIP1 α) [MIP1 α], MIP1 β , liver and activation regulated chemokine (LARC) [LARC], I309, hemofiltrate CC-chemokine -1 (HCC-1) [HCC-1], thymus and activation regulated chemokine (TARC) [TARC] or chemokine beta 8 (Ck β 8) [Ck β 8].

8. (Amended) The peptide of claim 1 [or 2] which is a peptide of a CXC chemokine.

9. (Amended) The peptide of claim 8 wherein the CXC chemokine is interferon inducible protein 10 (IP-10) [IP-10], platelet factor-4 (PF-4) [PF-4], stromal cell-derived factor-1 (SDF-1 α) [SDF-1], NAP-2, growth regulated oncogene alpha (GRO α) [GRO α], GRO β , GRO γ or epithelial neutrophil activating peptide-78 (ENA78) [ENA78].

B3 11. *Sub D3* (Amended) A CRD cyclic reverse D sequence (CRD) derivative of a peptide of a chemokine [peptide 3] or a variant thereof.

B4 Please add the following new claims:

Sub 4 42. (New) The peptide of claim 4 which is Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:7).

B5 43. (New) The derivative of claim 11 which is CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

Remarks

Reconsideration and withdrawal of the rejections of the claims, in view of the amendments and remarks presented herein, is respectfully requested. Claims 1, 3-4, 6-9, and 11 are amended, claims 2, 5 and 12-41 canceled, and claims 42-43 added. The pending claims are claims 1, 3-4, 6-11 and 42-43.

Claims 2 and 13-41 are canceled solely in response to the restriction requirement and